Maxtrid

Dutasteride, the active ingredient in Maxtrid, is a 5-alpha-reductase inhibitor presented as an oral tablet for oral use. It treats benign prostatic hyperplasia in men and is also used off‑label for male pattern hair loss.

GNH USA supplies Maxtrid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Dutasteride acts on the hormonal pathway that drives prostate growth and androgen‑related hair loss. - Benign prostatic hyperplasia (BPH): reduces prostate volume and improves urinary flow in men with enlarged prostate. - Male pattern hair loss (off‑label): may slow hair loss progression and promote regrowth of scalp hair.

Adverse reactions may occur with dutasteride therapy.

Common Side Effects: - Decreased libido: reduced sexual desire. - Erectile dysfunction: difficulty achieving erection. - Ejaculation disorders: reduced volume or pain. - Breast tenderness or enlargement: mild swelling of breast tissue. - Decreased semen volume: lower ejaculate amount. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or anaphylaxis. - Breast cancer: rare malignant growth in breast tissue. - Severe liver injury: jaundice, elevated enzymes. - Testicular pain: unexplained scrotal discomfort. - High‑grade prostate cancer: potential increased risk of aggressive disease.

Before initiating dutasteride, several safety considerations are recommended. - PSA monitoring: regularly assess prostate‑specific antigen levels. - Liver function: evaluate hepatic enzymes prior to use. - Pregnancy risk: avoid handling by women who are or may become pregnant. - Cardiovascular assessment: consider baseline blood pressure and heart disease. - Concomitant meds: review other drugs for additive effects. - Store at ambient temperature: keep in the original pack, protect from moisture.

Dutasteride can interact with several medication classes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase dutasteride exposure. - Co‑administration with other 5‑alpha‑reductase inhibitors: risk of excessive DHT suppression. - Testosterone therapy: may counteract dutasteride’s effect.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise dutasteride levels. - Antiretroviral agents (e.g., ritonavir): require monitoring of plasma concentrations. - Alpha‑blockers (e.g., tamsulosin): may enhance hypotensive effects when combined.